Výsledky vyhledávání - "Yong Jiang Hei"

Akademický článek

Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.

Autor: Michael B Bass, Bin Yao, Yong-Jiang Hei, Yining Ye, Gerard J Davis, Michael T Davis, Barbara A Kaesdorf, Sabrina S Chan, Scott D Patterson

Publikováno v: PLoS ONE, Vol 9, Iss 10, p e108048 (2014)

We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.Placental growth factor was evaluated at baseline and

Externí odkaz: https://doaj.org/article/d3ebf97e97f0499b9c74773db40ee917

Zobrazit plný text záznamu

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid

Autor: Janet E. Brown, Matthew Smith, Richard J. Cook, John W. Seaman, Pierre Major, Ker Ai Lee, Ming Zheng, F. Saad, Robert E. Coleman, Allan Lipton, Yong Jiang Hei

Publikováno v: Journal of Clinical Oncology. 23:4925-4935

Purpose Three large, randomized trials of patients with bone metastases recently demonstrated that zoledronic acid reduces the risk of skeletal-related events. These trials provide an opportunity for investigating the correlation between bone metabol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4941b2c1873ae0e2e9eaa59074c36b3
https://doi.org/10.1200/jco.2005.06.091

Zobrazit plný text záznamu

[Untitled]

Autor: John H. McNeill, Xunsheng Chen, Sepehr Farahbakhshian, Yong-jiang Hei, Mary L. Battell

Publikováno v: Molecular and Cellular Biochemistry. 178:367-375

To explore the mechanism underlying the insulin-mimetic actions of vanadium and selenium we examined their effects on the mitogen activated protein/myelin basic protein kinases (MAPK) and ribosomal S6 protein kinases, which are among the best charact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::042dc659069bda10267cc56adc066427
https://doi.org/10.1023/a:1006819906820

Zobrazit plný text záznamu

Skeletal Muscle Mitogen-Activated Protein Kinases and Ribosomal S6 Kinases: Suppression in Chronic Diabetic Rats and Reversal by Vanadium

Autor: Yong-jiang Hei, Steven L. Pelech, Xunsheng Chen, Jack Diamond, John H. McNeill

Publikováno v: Diabetes. 44:1147-1155

The mitogen-activated protein (MAP) kinases and ribosomal S6 protein kinases in the skeletal muscle of insulin-resistant long-term (2 and 6 months' duration) diabetic rats were investigated to understand further the changes in insulin intracellular s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::385b670750b8c7de842d271065fc0159
https://doi.org/10.2337/diab.44.10.1147

Zobrazit plný text záznamu

Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC)

Autor: Sergei Tjulandin, Anne Thomas, Tae Won Kim, Stefano Cascinu, Xuesong Guan, Timothy J. Price, Yong Jiang Hei, Marc Peeters, Tien Hoang, Attili Venkatasatya Suresh, Jin Li, Paul Ruff

Publikováno v: ResearcherID

507 Background: ASPECCT demonstrated that panitumumab (pmab) was noninferior to cetuximab (cmab) for overall survival (OS). Ad hoc analyses from ASPECCT suggested that hypomag was associated with better outcomes for pmab and cmab (Price 2015). Howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc5e99625b3a69dee69abeb71d79b6b8
https://doi.org/10.1200/jco.2016.34.4_suppl.507

Zobrazit plný text záznamu

Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT

Autor: Yong Jiang Hei, Xuesong Guan, Jin Li, Attili Venkatasatya Suresh, Sergei Tjulandin, Paul Ruff, Tae Won Kim, Anne Thomas, Stefano Cascinu, Tien Hoang, Marc Peeters, Timothy J. Price

Publikováno v: Journal of Clinical Oncology. 34:519-519

519 Background: The phase 3 ASPECCT trial of pts with chemorefractory WT KRAS exon 2 mCRC demonstrated that pmab was noninferior to cmab for overall survival (OS). A previous subgroup analysis of hazard ratios (HRs) suggested that pts who had receive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87d1aa9a534e4ee32749364f47217bb6
https://doi.org/10.1200/jco.2016.34.4_suppl.519

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání